Patent ID: 11384062

Abstract:
A deuterated compound having the structure of Formula I: or a pharmaceutically acceptable salt, solvate, or prodrug thereof; or a salt of a prodrug thereof; or a hydrate or polymorph thereof; wherein Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y9′, Y10, Y10′, Y11, Y11′, Y12, Y12′, and Y13 are selected from the group consisting of hydrogen or deuterium, wherein at least one of Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y9′, Y10, Y10′, Y11, Y11′, Y12, Y12′, and Y13 is deuterium; and wherein each carbon is independently optionally replaced with 13C is disclosed herein. Pharmaceutical compositions comprising the compounds of Formula (I) and the use of the compounds as inhibitors of the enzyme poly ADP ribose polymerase (PARP) for the treatment of patients with BRCA-mutation positive ovarian cancer and BRCA-positive breast cancer is also disclosed herein.